TO STUDY THE EFFECT OF COMBINATION OF METFORMIN, GLIMEPRIDE VOGLIBOSE IN TCF7L2 GENE ASSOCIATED TYPE 2 DIABETES MELLITUS.

Abstract

Background:The TCF7L2-gene (TCF7L2; Transcription factor 7-like 2) involves in regulation of cellular
proliferation and differentiation. It also increased risk for type 2 diabetes (T2D), dose effect were reported for
the rs7903146 variant. The risk alleles of TCF7L2 gene involves in progression of impaired glucose tolerance to
diabetes prospectively and an increased severity of the disease
Material and Methods:Prospective, randomised study. Combination of Metformin, Glimepride Voglibosehas
been prescribed in TCF7L2 gene associated type 2 diabetes mellitus patients s
Results: TCF7L2 gene is associated with Type 2 diabetes mellitus. Genetic investigation was done in all 40
patients three genotypes have been identified 10 patients were on CC, 12 patients were on CT and 18 patients
were on TT genotypes.Baseline values are higher in TT genotype when compared with CT & CC genotypes.
There were significant improvement in blood glucose levels were as a controlled lipid profile was observed in
CC genotype but no significant was observed in CT, TT and in group
Conclusion:Patients HbA1c ranges from <9.0 - 9.5 % prescribed with triple drug combination therapy of
metformin, Glimepride, voglibose shows significant improvement in blood glucose levels in all three genotypes
but no significant was observed in CT, TT genotypes. As a result combination of triple drug combination
therapy of metformin with glimepride, voglibose is the better drug of choice in CC genotype associated type 2
diabetes mellitus after 3 months of treatment.